Methamphetamine (METH) abuse is a serious social and health problem worldwide. At present, there are no effective medications to treat METH addiction 1 . Here, we report that aggregated single-walled carbon nanotubes (aSWNTs) significantly inhibited METH self-administration, METH-induced conditioned place preference and METH-or cue-induced relapse to drugseeking behaviour in mice. The use of aSWNTs alone did not significantly alter the mesolimbic dopamine system, whereas pretreatment with aSWNTs attenuated METH-induced increases in extracellular dopamine in the ventral striatum. Electrochemical assays suggest that aSWNTs facilitated dopamine oxidation. In addition, aSWNTs attenuated METHinduced increases in tyrosine hydroxylase or synaptic protein expression. These findings suggest that aSWNTs may have therapeutic effects for treatment of METH addiction by oxidation of METH-enhanced extracellular dopamine in the striatum.
. In contrast to their wide implications, little is known about the biological effects of the SWNTs themselves. We and others have reported that low doses of SWNTs are neuroprotective in animal models of Alzheimer's disease 4 and strokes 5 ; SWNTs were also reported to alter mitochondrial function and intracellular energy metabolism 6, 7 . Strikingly, recent studies showed that nanoparticle-coated electrodes are highly sensitive and effective in the adsorption and oxidation of dopamine, largely through increasing the electroactive surface areas [8] [9] [10] . Given the important roles of dopamine in the regulation of locomotion and goal-directed motivational behaviours such as drug abuse and addiction 11 , we hypothesized that SWNTs might be useful for the treatment of drug addiction by rapidly adsorbing and oxidizing the extracellular dopamine produced by drugs of abuse. METH is a highly potent psychostimulant and a dopamine releaser 12 . We therefore investigated the effects of SWNTs on METH-enhanced extracellular dopamine and METH addiction-related behaviour.
There are two types of SWNTs-individual SWNTs (iSWNTs) and aggregated SWNTS (aSWNTs)-which exhibit different bioactivities, as we demonstrated previously 7 . iSWNTs have an average size of 1-2 nm × 0.1-1 μm, whereas aSWNTs form aggregated bundles with average sizes of 15-20 nm × 0.1-1 μm ( Supplementary Fig. 1a,b) . The length distribution, ratio of metallic and semiconducting SWNTs and the low disordered carbon signal to graphitic signal bands (D/G ratio) of both types of SWNTs ( Supplementary  Fig. 1c,d ) are similar to values in the literature 7 .
As it is difficult to penetrate the blood-brain barrier, SWNTs were injected locally into a lateral cerebral ventricle in this study. We first evaluated the potential neural toxicity of intracerebroventricular (i.c.v.) microinjection of SWNTs in mice. Supplementary Fig. 2 shows that i.c.v. microinjection of iSWNTs or aSWNTs (1 or 2 ng) had no effect on animal body weight, feeding, drinking or locomotor behaviour compared with the vehicle (0.01% sodium deoxycholate in artificial cerebrospinal fluid) control group. There was no detectable alteration in cellular morphology in the prefrontal cortex (PFC) or striatum as assessed by hematoxylin and eosin staining of cell nuclei or terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)-staining of DNA fragments 24 h or 2 weeks after SWNT administration ( Supplementary Fig. 3 ). We then examined the effects of SWNTs on the mesolimbic dopamine system. We did not find significant changes in either tyrosine hydroxylase (TH)-or dopamine transporter (DAT)-immunostaining in the midbrain of mice after SWNT administration ( Supplementary Fig. 4a-c) . SWNTs also failed to alter striatal dopamine contents ( Supplementary Fig. 4d ) or the expression of TH, DAT or vesicular monoamine transporter 2 (VMAT2) in the striatum ( Supplementary Fig. 4e ). These findings suggest that i.c.v. microinjection of SWNTs alone had no significant adverse effects on general behaviour or on the mesolimbic dopamine system.
It is well documented that the rewarding and psychostimulating effects of METH are mediated by the activation of the mesolimbic dopamine system, in which METH causes a massive dopamine release in the projection areas of the brain such as the ventral striatum and PFC that SWNTs might be effective in the attenuation of METH addictionrelated behaviour by rapid adsorption and oxidization of the excess extracellular dopamine due to METH. To test this hypothesis, we first observed the effects of SWNTs on intravenous METH selfadministration, one of the most commonly used animal models for studying drug reward and addiction 13 . Figure 1a shows the general experimental procedure. Figure 1b shows that i.c.v. microinjections of iSWNTs into the lateral ventricle (1 or 2 ng, 30 min before the test) had no effect on METH self-administration. However, i.c.v. microinjections of the same doses of aSWNTs produced a significant reduction in METH self-administration (Fig. 1c) . This effect lasted less than 24 h (Fig. 1d) . Figure 1e shows the patterns of METH self-administration before and after aSWNT administration: the aSWNTs caused cessation of METH self-administration during a 3-hour-long test session. We then examined the effects of aSWNTs on relapse to drugseeking behaviour, a key issue in human drug addiction 13, 14 . We used the animal model of incubation of craving 14 , in which animals were first allowed intravenous METH self-administration and then subjected to three weeks of withdrawal in their home cages. When the animals were re-exposed to the same self-administration chambers, the drug-associated contextual stimuli (cues) induced robust lever-pressing (drug-seeking behaviour) in the absence of METH reinforcement. Pretreatment with aSWNTs (1 or 2 ng by i.c.v. microinjection 30 min before testing) almost completely blocked cue-induced drug-seeking behaviour (Fig. 1f) . Such cueinduced drug-seeking was repeated twice on day 3 (T2) and day 10 (T3) after the first test (T1), illustrating that this inhibitory effect lasted at least 3 days and then diminished 10 days after the first relapse test (Fig. 1f) . We also examined the effects of aSWNTs on METH-enhanced locomotion. Figure 1g shows that i.c.v. microinjection of aSWNTs inhibited METH-induced increases in locomotion in a dose-dependent manner.
Conditioned place preference (CPP) is another commonly used animal model to assess the rewarding properties of drugs or rewardrelated memory 13 . The CPP reinstatement test measures the ability of drug-related stimuli to trigger affective craving and relapse to drug-seeking behaviour 13 . Therefore, we used the CPP and reinstatement models (Fig. 2a) to confirm the findings observed in the above self-administration experiments. Before METH injection, animals showed no preference for any particular environment as assessed by METH-associated cue-induced CPP response in mice after 10 days of withdrawal from the last METH conditioning (Fig. 2d) , and the METH priming-induced reinstatement of CPP in mice after CPP extinction (Fig. 2e) . Taken together, these findings from multiple animal models suggest that aSWNTs have significant therapeutic effects in the attenuation of METH reward and relapse to METHseeking behaviour.
METH-induced dopamine release is mediated by blocking the intracellular VMAT2 that prevents dopamine re-uptake into intracellular vesicles, and therefore facilitates cytoplasmic dopamine release into the extracellular space via DAT 12 . To determine whether dopamine-related mechanisms underlie the above behavioural effects of aSWNTs, we measured the METH-induced changes in extracellular dopamine in the ventral striatum in the presence or absence of SWNTs in mice treated with METH (Fig. 3a) . We found that pretreatment with i.c.v. microinjection of aSWNTs, but not iSWNTs, significantly attenuated the METH-induced increase in extracellular dopamine in a dose-dependent manner (Fig. 3b) , whereas aSWNTs alone did not significantly alter the extracellular dopamine in the ventral striatum compared with the vehicle control group (Fig. 3c) . These findings suggest that a dopamine-dependent mechanism may underlie the behavioural effects of aSWNTs described above.
We then investigated how aSWNTs attenuate METH-enhanced extracellular dopamine. As glassy carbon electrodes coated with nickel oxide nanoparticles or carbon nanotubes are reported to be more sensitive than uncoated electrodes in adsorption and oxidation of dopamine [8] [9] [10] , we examined the effects of the SWNTs on dopamine oxidization using the same in vitro electrochemical methods. Figure 3d -f shows that SWNT-coated electrodes detected much larger tyrosine (a dopamine precursor) or dopamine oxidation currents than vehicle-coated electrodes in the presence of the same concentration (10 μM) of tyrosine or dopamine, suggesting that SWNTs potentiated dopamine oxidation on SWNT-coated electrodes. Notably, aSWNTs were more potent than iSWNTs in this action, which may in part explain the different efficacy of iSWNTs and aSWNTs in the behavioural and neurochemical tests described above.
We also examined the possible interaction between SWNTs and DAT in striatal membrane preparations. Co downwards (Fig. 3g) . Similarly, aSWNTs also dose-dependently reduced [ 3 H]-dopamine re-uptake (Fig. 3h) , suggesting that DAT may be another target acted on by SWNTs.
We next examined the effects of METH and SWNTs on the dopamine synthase (that is, on TH) and the dopamine degradation enzymes (such as monoamine oxidase (MAO) and catechol-Omethyltransferase (COMT)). We found that repeated METH administration (Fig. 4a) significantly upregulated TH expression in both the striatum and PFC (Fig. 4b) . This is consistent with previous findings 15, 16 . Pretreatment with SWNTs significantly reduced METH-enhanced TH expression in the striatum and PFC (Fig. 4c) . In contrast to TH, neither METH nor SWNTs altered MAO or COMT activities in the striatum or PFC (Fig. 4d,e and Supplementary Fig. 5 ), suggesting a selective action on dopamine synthesis, but not on dopamine degradation.
Finally, we observed the effects of SWNTs on METH-induced synaptic plasticity as recent findings indicate that repeated exposure to METH produces neuroadaptative changes in the dendritic structure and synaptic connections in the striatum and PFC 17, 18 that are thought to be associated with drug craving and relapse to drugseeking behaviour 18 . We therefore examined the METH-induced changes in synaptic marker protein expression, including presynaptic synaptophysin (SYP) and postsynaptic density-95 (PSD-95). Figure 5 shows that repeated METH administration significantly upregulated SYP (Fig. 5a,b) and PSD-95 (Fig. 5c,d ) expression in both the striatum and PFC, which was attenuated by SWNT pretreatment. Lastly, we used electron microscopy to observe the morphological changes in synapses where high densities of SYP and PSD-95 are expressed. A significant increase in the average synaptic density was observed in the brain after repeated METH treatments (Fig. 5e ). This was also attenuated by aSWNTs in the striatum (Fig. 5e,f ) and PFC (Supplementary Fig. 6 ).
In summary, the present study, for the first time, demonstrates that aSWNTs may have therapeutic potential for the treatment of METH dependence. This is based on the findings that aSWNTs not only inhibited the rewarding and psychomotor-stimulating effects of METH, but also inhibited METH-or cue-induced relapse to drug-seeking behaviour. These inhibitory effects seem to be dopamine-dependent as SWNTs significantly increased dopamine oxidation and attenuated METH-enhanced extracellular dopamine in the ventral striatum. In addition, SWNTs also inhibited [ 3 H]-WIN35,428 binding to DAT and [ 3 H]-dopamine reuptake, suggesting a possible interaction between SWNTs and DAT. However, another possible interpretation is that aSWNTs may also oxidize both of the radiolabelled compounds and therefore decrease the availability of radioligands in these assays. SWNTs also attenuated METH-enhanced expression of TH and the synaptic proteins SYP and PSD-95. The molecular mechanisms underlying these actions are unclear. A simple interpretation is that repeated METH administration causes massive dopamine release and depletes presynaptic dopamine, which leads to a series of adaptative changes in the synaptic structure or TH expression. Accordingly, the attenuation of METH-enhanced dopamine caused by SWNTs would counteract the METH-induced actions in protein expression. More studies are required to further address these issues.
A major concern about the use of SWNTs for the treatment of drug addiction is safety, particularly with regards to dopamine neuron toxicity after intracranial administration. At the doses used in the present study, we did not observe significant changes in general behaviours such as feeding, drinking, and locomotion. We also failed to observe significant neuronal toxicity in the striatum, PFC or midbrain after SWNT administration. Such low dopamine neurotoxicity may be related to the extremely low basal levels of extracellular dopamine (<1 × 10 −9 M) 19, 20 , extremely low doses of SWNTs (1-2 ng) and high biocompatibility of SWNTs after intracranial administration 21, 22 .
As stated above, SWNTs have been widely used in recent biomedical research 23 due to their favourable properties, which include their large surface areas, superior bundle strength, highly electrical conductivity and, more importantly, their highly electrostatic attraction to dopamine 23, 24 . We and others have recently started to explore the effects of SWNTs on the central nervous system 4, 5, 21 , and most of these studies have focused on the neurotoxicity of SWNTs at high doses 25 . The present study provides the first proof-of-concept evidence that aSWNTs may be useful for the treatment of METH addiction. Therefore, these nanotubes deserve further research as a new approach for the treatment of drug abuse and addiction.
Methods
Methods and any associated references are available in the online version of the paper.
Drugs. METH used in the self-administration and locomotion experiments was purchased from Sigma-Aldrich. METH (purity >98%) used in the CPP and neurochemical assays was obtained from the Liaoning Institute of Crime Detection and all other reagents were purchased from Sigma-Aldrich.
SWNT preparations. SWNTs were purchased from Chengdu Organic Chemicals, Chinese Academy of Sciences and further prepared as highly dispersed SWNTs, as described in our previous studies 7, 26 . In brief, iSWNTs and aSWNTs were sorted by density gradient ultracentrifugation. A 0.2-ml-thick layer of highly dispersed SWNTs was put on top of a three-layer of water-iodixanol density gradient (10% + 30% + 60% iodixanol in water). Centrifugation was carried out in a P40ST swing bucket rotor in a Himac CP80WX ultracentrifuge (Hitachi High Technologies) at 20°C with centripetal accelerations of about 200,000 g for 12 h. The bands containing separated SWNTs were manually retrieved from the centrifuge tube for subsequent characterization. All SWNT fractions were dissolved in 2 mg/ml sodium deoxycholate solution.
Atomic force microscopy. SWNTs were deposited by electrostatic adsorption onto mica. Freshly cleaved mica was pretreated with 2.0 mg ml -1 poly (diallyldimethylammonium chloride) (PDDA) for 1 h, and then soaked in the solution containing fractionated SWNTs for 30 min. This substrate was rinsed with water and then dried with air blowing. Atomic force microscopy measurements were performed on a Dimension 3,100 system (Digital Instruments) in tapping mode at room temperature (25-27°C) and 20-30% humidity. About 50 SWNTs were measured to obtain the length distribution.
UV-visible-near-infrared absorption spectroscopy. Absorbance measurements in the UV-vis-near-infrared range were carried out using a LAMBDA 950 UV-VIS spectrophotometer (Perkin Elmer). Separated fractions were measured with further dilution in a 1 mm path quartz cuvette. A cuvette filled with water was used in a double-beam geometry to subtract the background due to water absorption.
Raman spectroscopy. Raman spectroscopy at 785 nm excitation was performed using a Renishaw micro-Raman spectroscopy system (Renishaw).
Animals. Male mice with C57BL/6J genetic backgrounds were used for the METH self-administration and locomotion experiments. Animals used for the CPP experiments were group-housed (3-5 per cage) in a fully accredited animal facility and were maintained on a reversed 12 h light/dark cycle with food and water available ad libitum. Male Swiss mice (initial body weight 22-24 g, 6-8 weeks old) were bred at the Experimental Animal Facility of Shenyang Pharmaceutical University and used for the CPP and other neurochemical assays. Intravenous METH self-administration experiments were performed at the National Institute of Drug Abuse (NIDA) in accordance with the National Research Council's Guide for the Care and Use of Laboratory Animals, and were approved by the NIDA Animal Care and Use Committee in the USA. All animal procedures conducted in China followed the Regulations of Experimental Animal Administration and were approved by the State Committee of Science and Technology of China.
Surgery and microinjection. The surgical procedures used for the (i.c.v.) guide cannula implantation and microinjection were the same as we reported previously 19, 27 . The coordinates for the lateral ventricle are: anteroposterior -0.2 mm, mediolateral 1.0 mm, dorsoventral -2.5 mm 3 . After 7 days of recovery from the surgery, the experiment began. SWNTs were initially suspended in 2 mg ml -1 sodium deoxycholate, and then diluted (0.5 mg ml Measurements of food intake, water intake and body weight. After habituation to the experimental conditions, daily food intake, water intake and body weight were measured beginning from one day before the guide cannula implantation surgery and lasting for 40 days. Mice were housed individually in the home cages and fed with a standard laboratory diet (HuaFukang) and tap water. The daily food or water intake was calculated by the total amounts that were given and the remaining amounts after 24 h of consumption.
Locomotor activity. Locomotor activity was measured in locomotor chambers (Model ZIL-2, Institute of Materia Medica, Chinese Academy of Medical Sciences, China) as previously reported 27 . Before the testing, mice were habituated to the apparatus for 60 min for 2 consecutive days without any drug injection. Locomotor activity was recorded for 1 or 2 h after SWNTs administration.
Intravenous METH self-administration. Animal surgery, drug self-administration apparatus, drug self-administration and i.c.v. microinjection procedures were the same as described previously 19, 20 . In brief, after recovery from the surgery, each mouse was placed into a test chamber and allowed to lever-press for METH (0.05 mg kg -1 per infusion) delivered on a fixed-ratio 1 reinforcement schedule.
Each METH infusion was associated with the presentation of a stimulus light and tone. During the infusion time, extra responses on the active lever were recorded but did not lead to extra infusions. After stable METH self-administration was achieved, the animals were randomly divided into three groups-vehicle (n = 10), 1 ng SWNTs (n = 9) and 2 ng SWNTs (n = 9) to examine the effects of SWNTs on METH self-administration (Fig. 1a) . To avoid METH overdose, each animal was limited to a maximum of 50 METH injections per 3-hour-long testing session.
Cue-induced relapse to drug-seeking behaviour. After the completion of the above METH self-administration experiments, the animals were re-established for stable METH self-administration, followed by 3 weeks of withdrawal in the housing facility. On the test day, the mice were again placed into the self-administration chambers to observe METH-associated cue-induced lever-pressing (drug-seeking behaviour) in the presence or absence of SWNT pretreatment (0, 1 or 2 ng by i.c.v. microinjection given 30 min before the test). This cue-induced relapse test was repeated twice 2 days (T2) and 9 days (T3) after T1 in the absence of further aSWNT administration (Fig. 1a) .
CPP. The experimental procedures for METH-induced CPP are the same as reported previously 28, 29 . The pre-CPP test was performed to determine the amount of time that the animals spent in each chamber of the CPP device before METH administration. Animals that showed a significant preference (>10 min) for any particular environment in the pre-CPP test were excluded from the study. Each conditioning session includes METH-paired conditioning (1 h) and saline-paired conditioning (1 h) in a counterbalanced manner across all mice and chambers. During these sessions, mice were administered with METH (2 mg kg -1 by intraperitoneal (i.p.) injection every other day, and then were put into the METHpaired chambers for 1 h. Each animal received a total of 3 METH injections and 3 saline injections during the conditioning phase. Mouse CPP was recorded using a video camera and scored by a highly trained observer blinded to the treatments.
Effects of SWNTs on METH-induced CPP. After the pre-CPP test, one group of mice was randomly divided into 6 subgroups to observe the effects of the SWNTs on the acquisition of METH-induced CPP. In this study, SWNTs (0, 1 or 2 ng by i.c.v. microinjection) were given immediately before the first METH injection (Fig. 2a, Exp. 1 ).
Effects of SWNTs on CPP extinction. Another group of mice was used to observe the effects of SWNT pretreatment on the extinction response of METH-induced CPP (Fig. 2a, Exp. 2). In this experiment, each dose of SWNTs was given immediately before the first extinction session. During the extinction sessions animals were reexposed to the same CPP chambers, but without METH or saline injections. The CPP scores were compared between the different treatment groups.
Effects of SWNTs on cue-induced CPP response. After METH-induced CPP was established, another group of mice underwent 10 days of withdrawal in their home cages in the animal facility. Then these animals were re-exposed to the same CPP chambers to observe the effects of SWNTs (0, 1 or 2 ng by i.c.v. microinjection 12 h before the test) on the METH-associated cue-induced CPP response (Fig. 2a, Exp. 3).
Effects of SWNTs on METH-induced reinstatement of CPP. After the acquisition and extinction of METH-induced CPP, another group of animals was used to observe the effects of SWNTs on the METH-induced reinstatement of CPP (Fig. 2a, Exp. 4 ). After METH (1 mg kg -1 by i.p. injection) was given, animals were placed in the same CPP chambers with access to either side for 15 min. METH-induced reinstatement of CPP were measured. At the end of the experiments, the mice were anesthetized and perfused with saline, and the brain was removed for the follow-up studies including Western blots, ELISA and histological synaptic density examination.
In vivo microdialysis. The in vivo microdialysis procedures are the same as previously described 19, 20, 30 . In brief, in vivo microdialysis was performed in mice during the reinstatement test. The coordinates for the ventral striatum guide cannula implication are anteroposterior +1.4 mm, mediolateral ±2.0 mm, dorsoventral −3.5 mm. After 7 days of recovery from the surgery, a microdialysis probe was inserted into the ventral striatum via the pre-implanted guide cannula 12 h before microdialysis sample collection. SWNTs were given around 12 h before METH injection (that is, immediately before probing). After dialysate dopamine levels were stabilized, three baseline samples were collected, and then METH was given. Extracellular fluid samples were successively collected and simultaneously analysed every 20 min for 2-3 h after METH administration. After the completion of the experiments, mice were anesthetized and perfused transcardially with physiological saline followed by 10% paraformaldehyde. The locations of the tips of the dialysis probes were verified histologically. The procedures for the subsequent dialysate or tissue dopamine quantification were identical to those we have reported previously 19, 20, 30 .
Standard hematoxylin and eosin (H&E) staining and TUNEL assay. H&E staining was used to determine possible neuronal death after SWNT administration. A TUNEL staining kit (Roche Molecular Biochemicals) was used to detect DNA fragments (or cell death) according to the manufacturer's instruction.
Western immunoblot assays. At 2 h after the above METH-induced reinstatement of CPP test, mouse brains were perfused, and the striatum and PFC tissues were collected for Western blot assays (n = 4). The immunoblot procedures are the same as reported previously 19 . The following antibodies were used in this study: TH rabbit polyclonal antibody (Novus Biologicals, #NB300-109, 1:1,000), mouse antisynaptophysin (SYP) monoclonal antibody (Chemincon, #MAB368, 1:1,000), anti-PSD-95 monoclonal antibody (Millipore, #4-1066, 1:1,000), DAT rabbit polyclonal antibody (Novus Biologicals, #NB300-254, 1:1,000), and β-actin (Cell signaling Technologies, #A2066, 1:1,000).
Immunohistochemistry. The procedures for TH-and DAT-immunostaining are the same as we reported previously 19 . Briefly, after brain perfusion and fixation, 20-µm-thick coronal sections were cut for immunohistochemistry assays. For immunofluorescent examination, the brain sections were first incubated with a 5% goat serum containing 0.2% Triton X-100 for 1 h, and then incubated with TH (1:500) and DAT (Millipore, #MAB369, 1:200) antibodies at 4°C overnight. After being washed 3 times with PBS, the sections were incubated with Alexa-Fluor 488-and Alexa-Fluor 594-conjugated secondary antibodies (1:250, Invitrogen) for 1.5 h at room temperature, and then washed again with PBS. The TH-or DATimmunostaining images were taken using a laser scanning confocal microscope (LSM 510 META, Carl Zeiss MicroImaging). The Image J software was then used for TH or DAT quantitative assays.
Synaptic density measurement. After brain perfusion at 24 h after the METHinduced reinstatement test, the striatum and PFC tissues were then dissected and fixed in 1% osmium tetroxide/1.25% potassium ferrocyanide in 0.15 M sodium phosphate buffer for 1 h. Samples were dehydrated in a graded ethanol series, followed by propylene oxide, and were infiltrated and embedded in Polybed 812 resin (Polysciences). Ultrathin (70 nm) sections were taken, mounted on 200 mesh copper grids and stained with uranyl acetate and lead citrate. The ultrathin sections were observed and photographed using a HT7700 transmission electron microscope (Hitachi High Technologies). Synapses were identified according to well-established criteria 31, 32 . The synaptic density was measured quantitatively in both the striatum and PFC (∼20 image fields from 4 mice in each group) according to methods described previously 32 .
MAO activity assay. The PFC or striatum tissues were prepared using a mitochondrial extraction kit (Solarbio). After homogenization, brain tissue MAO activity was measured using a Monoamine Oxidase Assay Kit (Sigma). To determine the potential effects of SWNT on MAO activity, different doses of SWNTs were incubated with prepared tissues for 25 min. The specific MAO-B inhibitor pargyline was used as positive control. After the incubation, MAO reacted with p-tyramine, a substrate for MAO, resulting in the formation of H 2 O 2 , which was detected by a fluorimetric method (lex = 530/lem = 585 nm).
COMT activity assay. Brain tissue COMT activity was measured using an ELISA kit (Uscn Life Science). Briefly, protein samples were incubated with different doses of SWNTs for 20 min, and then COMT was reacted with a TMB substrate and a biotinconjugated antibody specific to COMT. Horseradish peroxidase (HRP)-conjugated Avidin exhibited a change in colour, which was detected spectrophotometrically at a wavelength of 450 ± 10 nm.
[ 3 H]-dopamine uptake assay. Striatal tissues were homogenized with a Teflon glass homogenizer in ice-cold phosphate buffer and subsequently centrifuged at 1,000 g for 12 min at 4°C. The resulting supernatant was centrifuged again at 12,500 g for 15 min to obtain the synaptosomal fraction. Synaptosomes were re-suspended at 50 mg ml -1 in an assay buffer (134 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl 2 , 1.4 mM MgSO 4 , 3.3 mM NaH 2 PO 4 , 12.7 mM Na 2 HPO 4 , 11 mM glucose, and 1 mM ascorbic acid; pH 7.4) in the presence of 20 or 200 nM [ 3 H]-dopamine (specific activity: 40 Ci mmol -1 , Perkin Elmer Life Sciences). Eight concentrations of unlabelled dopamine were used to make a standard curve (data not shown). Ascorbic acid (10 µM) and pargyline (10 µM) were added to prevent monoamine and catecholamine oxidation and degradation. The striatal synaptosomes were incubated with or without SWNTs (0.05 ng mg -1 tissue) for 30 min at 37°C. 5-HT (10 μM) reuptake inhibitor fluoxetine was added to the mixtures to prevent 5-HT transporter uptaking [ 3 H]-dopamine. Non-specific uptake was measured in the presence of 150 µM dopamine. Specific uptake was determined by subtraction of non-specific uptake from the total uptake. The reaction was stopped by adding 1 ml of ice-cold assay buffer, and the samples were rapidly filtered through Whatman GF/C glass microfibre filters (Brandel), washed three times with an ice-cold 0.32 M sucrose solution. The radioactivity on the filters was measured by micro-β 1450-Trilux using the liquid-scintillation counter mode. All samples were assayed in triplicate.
[ 3 H]-WIN35,428 binding assays. Striatal synaptosome preparation was the same as described above. The synaptosome pellets were then re-suspended at 100 mg ml -1 (wet weight of tissue) in the assay buffer and then incubated with different concentrations of [ 3 H]-WIN35,428 (∼10 nM; Specific activity: 84 Ci mmol -1 , Perkin-Elmer Life Sciences, ranging between 0-10 nM) on ice for 60 min. The nonspecific binding was obtained by using 30 µM benztropine. Ascorbic acid (10 µM) was added to block dopamine oxidation. Vacuum filtration with triple washes was performed using Whatman GF/C glass microfiber filters, and the resulting radioactivity on the filters was measured as described in the above [ 3 H]-dopamine uptake assay. All samples were assayed in triplicate and incubated at 4°C for 120 min in the presence or absence of SWNTs (0.05 ng mg -1 striatal synaptosome tissue).
SWNT-coated electrode preparation. SWNTs were coated on indium tin oxide (ITO) electrodes using layer-by-layer adsorption. Cleaned ITO electrodes were first reacted with 10 µl of PDDA (2.0 mg ml -1 in a 10 mM phosphate buffer, pH 7.4) for 1 h and then washed carefully. The PDDA-coated electrode was then incubated with 10 µl of 0.05 mg ml -1 SWNTs in 10 mM phosphate (pH 7.4) for 1 h, and then washed carefully.
Electrochemical measurements. A CHI 660D workstation (CH Instruments) was used to collect electrochemical data. The measurements were performed using a three-electrode system. The SWNT-coated electrode served as the working electrode, a platinum wire was used as the auxiliary electrode, and the reference electrode was Ag/AgCl. All experiments were performed at room temperature in a phosphate buffer solution (10 mM, pH 7.4) as a background electrolyte.
Data analysis. All the data are expressed as mean ± s.e.m. The density of the immunoblot band was quantified using Image J software (NIH Image). The statistical significance was determined using one-way or two-way ANOVA. Dunnett's multiple comparison tests were used to analyse the betweengroup differences.
